Previous close | 287.00 |
Open | 286.75 |
Bid | 287.95 x 0 |
Ask | 288.30 x 0 |
Day's range | 285.95 - 286.75 |
52-week range | 199.70 - 300.00 |
Volume | |
Avg. volume | 18 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
A renaissance is stirring in cholesterol treatment, and it could drive Merck, Novartis and other stocks higher, while delivering new choices for millions of patients.
A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.
Key Insights Amgen's estimated fair value is US$537 based on 2 Stage Free Cash Flow to Equity Amgen's US$309 share...